Intuitive Surgical is rated a Hold with a price target of $426.65, implying a 9.17% upside. The company's growth potential lies in untapped Ambulatory Surgery Center (ASC) procedure volume and the limited threat from remanufacturing, which currently has less than 3% penetration and approvals for only 4 of over 45 instruments. Despite trading at a premium valuation due to strong growth and high recurring revenue, the stock's upside is considered moderate. Investors should watch how the ASC market develops and remanufacturing trends evolve.
Deutsche Bank upgraded Intuitive Surgical from Sell to Buy despite a 33% stock drop in 2026, citing its attractive valuation with a forward P/E ratio of 35, well below its five-year average of 54. The company maintains a strong market position with o...
Intuitive Surgical's stock has fallen over 30% this year, yet the company continues to grow its installed base of surgical robots and recurring revenue from instruments and services. The da Vinci system fleet expanded 12% in Q2 2026, with recurring r...
